945994-99-0

Usage

Uses

Used in Organic Synthesis:
Phenyl [3-tert-butyl-1-(3-[tert-butyl(dimethyl)silyl]oxy-4-chlorophenyl)-1H-pyrazol-5-yl]carbamate is used as a key intermediate in organic synthesis for the creation of various complex organic molecules, leveraging its unique structural features and reactivity.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, phenyl [3-tert-butyl-1-(3-[tert-butyl(dimethyl)silyl]oxy-4-chlorophenyl)-1H-pyrazol-5-yl]carbamate is used as a chemical scaffold for the design of new pharmaceutical agents, due to its potential biological activities and the presence of a pyrazole ring, which is recognized for its utility in drug discovery.
Used in Drug Development:
Phenyl [3-tert-butyl-1-(3-[tert-butyl(dimethyl)silyl]oxy-4-chlorophenyl)-1H-pyrazol-5-yl]carbamate is utilized in drug development as a starting point for the synthesis of potential therapeutic agents, taking advantage of its structural attributes and the pharmacophoric elements it contains.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, phenyl [3-tert-butyl-1-(3-[tert-butyl(dimethyl)silyl]oxy-4-chlorophenyl)-1H-pyrazol-5-yl]carbamate is used as a precursor for the synthesis of new drug candidates, with the aim of discovering compounds with improved efficacy, selectivity, and pharmacokinetic properties.
Used in Chemical Research:
Phenyl [3-tert-butyl-1-(3-[tert-butyl(dimethyl)silyl]oxy-4-chlorophenyl)-1H-pyrazol-5-yl]carbamate serves as a subject of chemical research to explore its reactivity, stability, and potential interactions with biological targets, contributing to the advancement of chemical knowledge and the discovery of new chemical reactions.

Upstream product

• 945994-85-4 5-(5-amino-3-tert-butyl-1H-pyrazol-1-yl)-2-chlorophenol 
• 945994-97-8 3-tert-butyl-1-(3-{[tert-butyl(dimethyl)silyl]oxy}-4-chlorophenyl)-1H-pyrazol-5-amine 
• 1885-14-9 phenyl chloroformate 
• 59997-51-2 trimethylacetylacetonitrile 

Downstream Products

• 1028275-13-9 1-[3-tert-butyl-1-(4-chloro-3-hydroxyphenyl)-1H-pyrazol-5-yl]-3-[2-({3-[2-(2-hydroxyethoxy)phenyl][1,2,4]triazolo[4,3-a]pyridin-6-yl}thio)benzyl]urea 

Relevant academic research and scientific papers

Design and synthesis of inhaled p38 inhibitors for the treatment of chronic obstructive pulmonary disease

This paper describes the identification and optimization of a novel series of DFG-out binding p38 inhibitors as inhaled agents for the treatment of chronic obstructive pulmonary disease. Structure based drug design and "inhalation by design" principles have been applied to the optimization of the lead series exemplied by compound 1a. Analogues have been designed to be potent and selective for p38, with an emphasis on slow enzyme dissociation kinetics to deliver prolonged lung p38 inhibition. Pharmacokinetic properties were tuned with high intrinsic clearance and low oral bioavailability in mind, to minimize systemic exposure and reduce systemically driven adverse events. High CYP mediated clearance and glucuronidation were targeted to achieve high intrinsic clearance coupled with multiple routes of clearance to minimize drug-drug interactions. Furthermore, pharmaceutical properties such as stability, crystallinity, and solubility were considered to ensure compatibility with a dry powder inhaler. 1ab (PF-03715455) was subsequently identified as a clinical candidate from this series with efficacy and safety profiles confirming its potential as an inhaled agent for the treatment of COPD.

TRIAZOLOPYRIDINE COMPOUNDS

A compound of formula (Ia): or a pharmaceutically acceptable salt and/or solvate (including hydrate) thereof, or a compound of formula (Ib): or a pharmaceutically acceptable salt and/or solvate (including hydrate) thereof, and the use of a compound of formula (Ia) or (Ib) in the treatment of a TNF -mediated disease, disorder, or condition, or a p38 -mediated disease,. disorder, or condition, in particular the allergic and non-allergic airway diseases, more particularly obstructive or inflammatory airways diseases, preferably chronic obstructive pulmonary disease.

PYRIDINONE PYRAZOLE UREA AND PYRIMIDINONE PYRAZOLE UREA DERIVATIVES

This invention is directed generally to substituted pyridinone and pyrimidinone compounds that generally inhibit p38 kinase, TNF, and/or cyclooxygeπase activity. Such substituted pyridinone and pyrimidinone compounds include compounds generally corresponding in structure to the following formula: wherein Z, n, R1, R2a, R2b, R2c, R2d, R2e, R3a, R3b R3c, R3d, R4, R5, R6, R7a, R7b, R7c, R7d and R7e are as defined in this specification. This invention also is directed to compositions of such substituted pyridinones and pyrimidinones (particularly pharmaceutical compositions), and methods for treating disorders (typically pathological disorders) associated with p38 kinase activity, TNF activity, and/or cyclooxygenase-2 activity.